Oncopia Therapeutics Inc. (dba Proteovant Therapeutics Inc.) and the University of Michigan have jointly patented molecular glue degraders targeting cereblon (CRBN) and acting as zinc finger protein Helios (IKZF2) degradation inducers.

Eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers have been reported in a Bristol Myers Squibb Co. patent as potentially useful for the treatment of cancer.

Atrin Pharmaceuticals Inc. has disclosed ATR kinase inhibitors potentially useful for the treatment of cancer.

Zydus Lifesciences Ltd. has patented compounds reported to be useful for the treatment of osteoarthritis.

Prism Biolab Co. Ltd. has identified new 7-membered ring-fused compounds acting as Notch signaling inhibitors and reported to be potentially useful for the treatment of neuronal injury and neurodegenerative diseases.

Wading into the “muddied waters” of rounding the numbers used in a range claimed in two drug patents, the U.S. Court of Appeals for the Federal Circuit refused to set a “bright line rule.” Instead, it tossed a lower court win for Actelion Pharmaceuticals Ltd. against Mylan Pharmaceuticals Inc. and sent the case back to that court with instructions to consider the extrinsic evidence and its impact on the claim construction.

Hyperway Pharmaceutical Co. Ltd. and Shenzhen Hyperway Pharmaceuticals Co. Ltd. have disclosed new GTPase KRAS (G12D mutant) inhibitors.

Bioversys AG has prepared rifabutin analogues reported to be useful for the treatment of bacterial infections.

Substituted fluorinated N-propyl-pyrrolidine and n-propyl-azetidine compounds acting as estrogen receptor (ER) antagonists and selective estrogen receptor degradation (SERD) inducers have been reported in a Sanofi SA patent.

Enanta Pharmaceuticals Inc. has patented heterocyclic compounds potentially useful for the treatment of metapneumovirus (MPV), influenza and respiratory syncytial virus (RSV) infections.